Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stephens & Co. Reiterates Overweight on Steris, Maintains $250 Price Target

Author: Benzinga Newsdesk | February 09, 2024 02:12pm
Stephens & Co. analyst Jacob Johnson reiterates Steris (NYSE:STE) with a Overweight and maintains $250 price target.

Posted In: STE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist